Neil Moss

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

High Impact

Role not yet determined Is this you? Add your title

University of Arkansas

Also affiliated: Boehringer Ingelheim (Germany) (1993–2009); University of British Columbia (1984–2010); Queen's University (2024); University of Oxford (1989); Boehringer Ingelheim (Brazil) (1999); Boehringer Ingelheim (Japan) (1994–2012); Boehringer Ingelheim (Egypt) (1993–1995); Boehringer Ingelheim (Canada) (1993–2001); Boehringer Ingelheim (France) (1994–2009); Boehringer Ingelheim (United States) (2002–2017); Boehringer Ingelheim (Spain) (1999)

24 h-index 62 pubs 2,492 cited

Research Areas

Biomedical Subjects

Links

Lab Website

OverviewAI-generated summary

Neil Moss's research centers on the development of enzyme inhibitors, with a particular focus on p38 mitogen-activated protein kinases (MAPK). His work has investigated novel allosteric binding sites for these inhibitors, as demonstrated by studies on BIRB 796 and its analogues. Moss has explored structure-activity relationships to optimize lead compounds, contributing to the identification of potential clinical candidates for various therapeutic applications.

His publications also include work on other kinase inhibitors, such as those targeting Lck kinase and MAPKAP-K2. These studies often involve molecular modeling and structural analyses to understand ligand binding and predict efficacy. Moss's research has been recognized through a high-impact designation, reflecting his contributions to the field as indicated by his h-index of 24 and over 2,400 citations across his 62 publications.

Metrics

h-index: 24
Publications: 62
Citations: 2,492

Selected Publications

Performance of heifers grazing native or introduced mixed warm-season grasses during summer months in south-central United States (2024)

Applied Animal Science 4 citations DOI OpenAlex

View all publications on OpenAlex →